Literature DB >> 16760318

Immunologic response to Haemophilus influenzae type b (Hib) conjugate vaccine and risk factors for carriage among Hib carriers and noncarriers in Southwestern Alaska.

Henry C Baggett1, Thomas W Hennessy, Lisa Bulkow, Sandra Romero-Steiner, Debra Hurlburt, Patricia Holder, Alan J Parkinson, Rosalyn J Singleton, Orin Levine, George M Carlone, Jay C Butler.   

Abstract

Continued Haemophilus influenzae type b (Hib) carriage in rural Alaska contributes to the ongoing risk of invasive disease. Community-wide Hib carriage surveys were conducted in three villages in southwestern Alaska. Sixteen carriers and 32 age- and village-matched controls were enrolled and were vaccinated with Hib oligosaccharide-CRM(197) conjugate vaccine. Serum immunoglobulin G (IgG) concentration, antibody avidity, and serum bactericidal activity (SBA) were measured prior to Hib vaccination and 2 and 12 months after vaccination. We identified no demographic or behavioral factors associated with Hib colonization. Prior to vaccination, Hib carriers had a higher IgG geometric mean concentration than controls did (8.2 versus 1.6 microg/ml; P < 0.001) and a higher SBA geometric mean titer (7,132 versus 1,235; P = 0.006). Both groups responded to vaccination with increased IgG and SBA. These data illustrate the role of Hib colonization as an immunizing event and show that Hib carriers in communities with ongoing transmission have no evidence of reduced immune responsiveness that may have put them at risk for colonization.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16760318      PMCID: PMC1489551          DOI: 10.1128/CVI.00077-06

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  36 in total

1.  Prevention of Haemophilus influenzae type b colonization by vaccination: correlation with serum anti-capsular IgG concentration.

Authors:  J Fernandez; O S Levine; J Sanchez; S Balter; L LaClaire; J Feris; S Romero-Steiner
Journal:  J Infect Dis       Date:  2000-10-09       Impact factor: 5.226

2.  Can Haemophilus influenzae type b disease be eliminated from the United States?

Authors:  M Santosham
Journal:  J Pediatr       Date:  2000-09       Impact factor: 4.406

3.  Reemergence of invasive Haemophilus influenzae type b disease in a well-vaccinated population in remote Alaska.

Authors:  K Galil; R Singleton; O S Levine; M A Fitzgerald; L Bulkow; M Getty; B A Perkins; A Parkinson
Journal:  J Infect Dis       Date:  1999-01       Impact factor: 5.226

4.  Randomized trial of the immunogenicity of fractional dose regimens of PRP-T Haemophilus influenzae type b conjugate vaccine.

Authors:  J Fernández; S Balter; J Feris; E Gómez; Z Garib; P L Castellanos; J Sánchez; S Romero-Steiner; O S Levine
Journal:  Am J Trop Med Hyg       Date:  2000-04       Impact factor: 2.345

5.  Antibodies to Haemophilus influenzae serotype b in the Netherlands a few years after the introduction of routine vaccination.

Authors:  S van Den Hof; H E de Melker; G A Berbers; P H van Der Kraak; M A Spaendonck
Journal:  Clin Infect Dis       Date:  2000-12-12       Impact factor: 9.079

6.  Antibody concentration and clinical protection after Hib conjugate vaccination in the United Kingdom.

Authors:  P T Heath; R Booy; H J Azzopardi; M P Slack; J Bowen-Morris; H Griffiths; M E Ramsay; J J Deeks; E R Moxon
Journal:  JAMA       Date:  2000-11-08       Impact factor: 56.272

7.  Experience with the prevention of invasive Haemophilus influenzae type b disease by vaccination in Alaska: the impact of persistent oropharyngeal carriage.

Authors:  R Singleton; L R Bulkow; O S Levine; J C Butler; T W Hennessy; A Parkinson
Journal:  J Pediatr       Date:  2000-09       Impact factor: 4.406

Review 8.  Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates.

Authors:  H Peltola
Journal:  Clin Microbiol Rev       Date:  2000-04       Impact factor: 26.132

9.  Progress toward eliminating Haemophilus influenzae type b disease among infants and children--United States, 1987-1997.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1998-11-27       Impact factor: 17.586

10.  Predictors for Haemophilus influenzae colonization, antibiotic resistance and for sharing an identical isolate among children attending 16 licensed day-care centers in Michigan.

Authors:  Cibele Barbosa-Cesnik; Rand S Farjo; May Patel; Janet Gilsdorf; Sandra I McCoy; Melinda M Pettigrew; Carl Marrs; Betsy Foxman
Journal:  Pediatr Infect Dis J       Date:  2006-03       Impact factor: 2.129

View more
  4 in total

1.  Antibody Binding and Complement-Mediated Killing of Invasive Haemophilus influenzae Isolates from Spain, Portugal, and the Netherlands.

Authors:  Elena Dudukina; Laura de Smit; Giel J A Verhagen; Arie van de Ende; José María Marimón; Paula Bajanca-Lavado; Carmen Ardanuy; Sara Marti; Marien I de Jonge; Jeroen D Langereis
Journal:  Infect Immun       Date:  2020-09-18       Impact factor: 3.441

2.  The effect of rituximab on vaccine responses in patients with immune thrombocytopenia.

Authors:  Ishac Nazi; John G Kelton; Mark Larché; Denis P Snider; Nancy M Heddle; Mark A Crowther; Richard J Cook; Alan T Tinmouth; Joy Mangel; Donald M Arnold
Journal:  Blood       Date:  2013-07-12       Impact factor: 22.113

3.  Serum IgM antibodies contribute to high levels of opsonophagocytic activities in toddlers immunized with a single dose of the 9-valent pneumococcal conjugate vaccine.

Authors:  Birgit Simell; Anu Nurkka; Nina Ekström; Noga Givon-Lavi; Helena Käyhty; Ron Dagan
Journal:  Clin Vaccine Immunol       Date:  2012-08-08

4.  Immune responses to vaccine-preventable diseases among toddlers and preschool children after primary immunization and first booster in Northwestern Algiers, Algeria.

Authors:  Nabila Benamrouche; Hassiba Tali Maamar; Samia Chemli; Houria Senouci; Kheira Rahal
Journal:  Heliyon       Date:  2018-06-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.